Tuesday, April 19, 2011
Cytokinetics Inc., of South San Francisco, said additional Phase IIa data of CK-2017357 in patients with amyotrophic lateral sclerosis showed that, at 24 hours after each of the 250-mg and 500-mg doses, dose-related increases in the change from the day one baseline in percent predicted muscle strength achieved nominal statistical significance for elbow flexion (p = 0.005 and 0.0004, respectively).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.